Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

British Journal of Cancer

Volumn 99, Issue 5, 2008, Pages 711-715

  Sherrill, B ^a   Amonkar, M M ^b   Stein, S ^b   Walker, M ^c   Geyer, C ^d   Cameron, D ^e  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Four Allegheny Center   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Breast cancer; Lapatinib; Q TWiST; Quality adjusted survival

Indexed keywords

CAPECITABINE; LAPATINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL ASSESSMENT; DATA ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; QUINAZOLINES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 50249188726     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604501     Document Type: Article

References (12)

1. Agency for Healthcare Research and Quality (2005) Calculating the US Population-Based EQ-5D Index Score. Rockville, MD, Available at: http://www.ahrq.gov/rice/EQ5Dscore.htm Accessed 17 October 2006
2. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat; e-pub ahead of print
3. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A (2001) Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358: 277-286
4. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18: 3302-3317
5. EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16: 199-208
6. Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 1772-1779
7. Gelber RD, Goldhirsch A, Cavalli F (1991) Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 114: 621-628
8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743
9. Glasziou PP, Simes RJ, Gelber RD (1990) Quality adjusted survival analysis. Stat Med 9: 1259-1276
10. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
11. Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D, Jassem J, Engelsman E, Duchateau L, EORTC Breast Cancer Group (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists' preferences. Eur J Cancer 39: 614-621
12. Revicki DA, Feeny D, Hunt TL, Cole BF (2006) Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 15: 411-423